Table 5.
1. Thrombocytopenia and MAHA/aMAHA. | |
2. Underling critical illness due to such conditions as. | |
√ Pathogen (bacterial; viral; fungal; rickettsial; parasitic) | |
√ Polytrauma (chest and lung; bone; skull/brain) | |
√ Pregnancy (preeclampsia; abruptio placenta; amniotic fluid embolism) | |
√ Cancer (breast; stomach; lung) | |
√ Surgery (heart; bowel; uterus; bone) | |
√ Transplant (liver; kidney; bone marrow) | |
√ Disease (autoimmune vascular disease; malignant hypertension) | |
√ Drug (cyclosporin; mitomycin C) | |
√ Toxin (venom; ricin; Shiga toxin) | |
3. Negative antibody against ADAMTS13. | |
4. Mild to moderately decreased activity of ADAMTS13 (20–70% of normal). | |
5. One or more organ phenotype dysfunction syndromes such as. | |
√ Pancreatitis. | |
√ Myocardial infarction. | |
√ ARDS. | |
√ Acute fulminant hepatic failure. | |
√ Acute adrenal insufficiency. | |
√ Rhabdomyolysis. | |
√ Non-occlusive mesenteric ischemia. | |
√ Hepato-renal syndrome. | |
√ Hepatic-encephalopathy. | |
√ Cardio-pulmonary syndrome. | |
√ Tissue gangrene. | |
√ Peripheral digit ischemic syndrome. |
+ Encephalopathy and ARF are common in both TTP and TTP-like syndrome
ARDS acute respiratory distress syndrome, TTP thrombotic thrombocytopenic purpura